1. Primary lung signet-ring cell carcinoma: a national analysis.
- Author
-
Mansur A, Saleem Z, Potter AL, Mathey-Andrews C, Senthil P, and Yang CJ
- Abstract
Background: Primary lung signet-ring cell carcinoma (LSRCC) is a rare form of aggressive lung cancer whose clinical features remain inadequately discerned. The objective of this study was to evaluate the clinicopathological characteristics and independent prognostic factors of primary LSRCC., Methods: Overall survival (OS) of patients with LSRCC, lung adenocarcinoma (LAC), and lung mucinous adenocarcinoma (LMAC) in the National Cancer Database from 2004 to 2018 was evaluated using Kaplan-Meier and multivariable Cox proportional hazards modeling. Independent prognostic indicators for patients with LSRCC were determined using multivariable Cox proportional hazards analysis., Results: A total of 1,705 LSRCC, 504,006 LAC, and 15,883 LMAC patients were included in our analysis. LSRCC histology was significantly associated with younger age, male sex, larger and more poorly differentiated tumors, later American Joint Committee on Cancer (AJCC) stage disease, higher clinical T, N, and M status, more use of chemotherapy, and less use of surgery when compared to LAC and LMAC patients. In unadjusted analysis, patients with LSRCC had significantly worse OS when compared to patients with LAC and LMAC. In multivariable analysis, patients with LSRCC experienced significantly worse OS when compared to only patients with LAC. Independent predictors of survival for patients with LSRCC were younger age, later year of diagnosis, lower Charlson/Deyo comorbidity condition scores, lower AJCC stage, higher income, smaller tumors, treatment with surgery, and receipt of chemotherapy., Conclusions: In this national analysis, LSRCC was found to be associated with distinct clinicopathological characteristics from those of LAC., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-102/coif). C.F.J.Y. serves as an unpaid editorial board member of Journal of Thoracic Disease from February 2023 to January 2025. He declares honoraria from AstraZeneca for summit participation and is on the advisory boards for AstraZeneca and Genentech. The other authors have no conflicts of interest to declare., (2024 AME Publishing Company. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF